# Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

> **NCT05870761** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Casey Cosgrove** · enrollment: 8 (actual)

## Conditions studied

- Recurrent Endometrial Serous Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Dostarlimab
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05870761
- **Lead sponsor:** Casey Cosgrove
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-17
- **Primary completion:** 2025-09-19
- **Final completion:** 2026-07-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870761, "Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05870761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*